The company has increased manufacturing capacity from pilot scale to 1 million liters annually, and can now assist customers ...

VERAXA Biotech AG, a developer of innovative cancer therapies, has announced a partnership with OmniAb, Inc. to create a bispecific antibody drug conjugate (bsADC) program aimed at treating solid ...

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward ...